Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept®, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability

NCT03633799 is registered in ClinicalTrials.gov with Sebela Women's Health Inc. as lead sponsor.

NCT NCT03633799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03633799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept®, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability
Lead sponsor
Sebela Women's Health Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 22, 2018
Completion date
September 22, 2027
Enrollment
1,620 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

women at risk for pregnancy